11 news items
Takeda To Present Long-Term Data From Phase 3 ADVANCE-CIDP 3 Clinical Trial Of HYQVIA In Patients With Chronic Inflammatory Demyelinating Polyneuropathy At PNS Annual Meeting
TAK
18 Jun 24
session on Sunday, June 23, 2024 at the Peripheral Nerve Society (PNS) Annual Meeting in Montreal, Canada.
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK
18 Jun 24
23, 2024 at the Peripheral Nerve Society (PNS) Annual Meeting in Montreal, Canada.
HYQVIA is the first
Takeda Presents Phase 2b Results for Narcolepsy Treatment at SLEEP 2024
TAK
3 Jun 24
2024, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society. TAK-861 is an investigational oral orexin
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK
3 Jun 24
, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society. TAK-861
Saturday, Takeda And Pfizer Announced Presentation Of Phase 3 HD21 Trial Results Evaluating Adcetris (Brentuximab Vedotin) In Combination With Chemotherapy At The American Society Of Clinical Oncology And European Hematology Association Annual Meeting
PFE
TAK
3 Jun 24
fj8znylls2qc44wkg617h9mtpsthwakhwtcw4weh1kr
PFE
TAK
1 Jun 24
with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology
9wu01wdz4 vlsecvfj
ACIU
TAK
13 May 24
as well as worldwide commercialization.
"At Takeda, we are committed to tackling some of society's most
5cjk4jsf6hyyppngfhgcyogbthwfj8ji1c
ACIU
TAK
13 May 24
to tackling some of society's most debilitating illnesses, including Alzheimer's disease. We are excited to partner with AC Immune on this ground-breaking
m6nmm9yt7b4n2 tkaaengp8208f70t
TAK
26 Apr 24
.
American Cancer Society. Cancer Facts & Figures 2024. Atlanta, American Cancer Society; 2024
ab6evgne0jipx7wy6wjie4d8m5mf0yeiitbnra340g rdzlv2y
TAK
22 Apr 24
to accelerate open innovation in early-stage drug discovery, and toward the creation of start-up companies for the benefit of society
89ob2p6m2qiqlwhknpo4ac5ugm
TAK
27 Mar 24
Society, confirms her full support for this pioneering initiative. She stressed that highlighting the challenges of this disease goes beyond the issue
- Prev
- 1
- Next